Health-related quality of life and patient-reported outcome measures in NASH-related cirrhosis-Reference-Cited by-同舟云学术

Health-related quality of life and patient-reported outcome measures in NASH-related cirrhosis

Published:2020-06 Issue:3 Volume:2 Page:100099
ISSN:2589-5559
Container-title:JHEP Reports
language:en
Short-container-title:JHEP Reports

Author:

McSweeney Lorraine,Breckons Matthew,Fattakhova Gulnar,Oluboyede Yemi,Vale Luke,Ternent Laura,Balp Maria-Magdalena,Doward Lynda,Brass Clifford A.,Beyer Fiona,Sanyal Arun,Anstee Quentin M.

Funder

Innovative Medicines Initiative 2

European Union's Horizon 2020

EFPIA

Novartis Pharma AG

European Commission

Abbvie

Allergan/Tobira

AstraZeneca

GlaxoSmithKline

Glympse Bio

Pfizer Ltd.

Vertex

Publisher

Elsevier BV

Subject

Gastroenterology,Hepatology,Immunology and Allergy,Internal Medicine

Reference66 articles.

1. Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention;Younossi;Nat Rev Gastroenterol Hepatol,2018

2. Progression of NAFLD to diabetes mellitus, cardiovascular disease or cirrhosis;Anstee;Nat Rev Gastroenterol Hepatol,2013

3. Evidence of NAFLD progression from steatosis to fibrosing-steatohepatitis using paired biopsies: implications for prognosis and clinical management;McPherson;J Hepatol,2015

4. Increased risk of mortality by fibrosis stage in nonalcoholic fatty liver disease: systematic review and meta-analysis;Dulai;Hepatology,2017

5. EASL–EASD–EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease;J Hepatol,2016

Cited by 37 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Creating a framework for an integrated novel ultrasound clinic for metabolic dysfunction-associated steatotic liver disease;British Journal of Healthcare Management;2024-06-02

2. Non-invasive biomarkers prognostic of decompensation events in NASH cirrhosis: a systematic literature review;Journal of Molecular Medicine;2024-05-16

4. The association between dietary inflammatory index (DII) scores and c-reactive protein (CRP) and nonalcoholic fatty liver disease (NAFLD) in a general population cohort;Clinical Nutrition ESPEN;2024-04

5. Steatotic Liver Disease: Pathophysiology and Emerging Pharmacotherapies;Pharmacological Reviews;2024-01-30